Vanguard Rocc Post Market Surveillance

Sponsor
Zimmer Biomet (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT03664791
Collaborator
(none)
450
9
194.3
50
0.3

Study Details

Study Description

Brief Summary

The objective of this project is to obtain prospective, multi-center, long term (10 year) clinical data on the Vanguard Rocc knee prosthesis. Patient and knee function will be collected along with knee stability, the knee motion, functional recuperation, radiographic and survivorship data.

Detailed Description

The Vanguard rotating platform knee prosthesis (Vanguard ROCC) was launched in March 2009. Therefore there is a need to show the safety and performance of the Vanguard ROCC at long term.

A maximum of 10 sites will be involved in this study. This number of clinical centers will permit assessment of consistency among a multitude of investigators.

Study Design

Study Type:
Observational
Actual Enrollment :
450 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Prospective, Multicentre Evaluation of the Vanguard Rocc Rotating Platform Knee Prosthesis - Clinical and Radiographic Outcomes
Actual Study Start Date :
Oct 23, 2009
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Vanguard Rocc knee implant

Patient in need for a total knee arthroplasty and who met the inclusion/ exclusion criteria and received the Vanguard Rocc implant

Procedure: Vanguard Rocc
Patient operated with the Vanguard Rocc knee prosthesis

Outcome Measures

Primary Outcome Measures

  1. Functional outcomes assessment [10 years]

    The American Knee Society Clinical Rating System (original method) : Evaluation of the knee joint and functional assessment of patients. Subscale knee assessment: judgement of pain (50 points), stability (25 points)and range of motion (25 points (5 degrees is 1 point). Flexion contracture, extension lag and malalignment should be dealt with as deductions. Maximum Knee score of 100 points. Subscale functional assessment: assessment of patient function for walking distance (50 points)and stair climbing (50points), with deductions for walking aids. Maximum Function score is 100 points.

Secondary Outcome Measures

  1. Radiographic outcomes assessment [10 years]

    The Knee Society Total Knee Arthroplasty Roentgenographic Evaluation and Scoring System by Ewald: radiographic assessment for component position, leg and knee alignment, and the prosthesis-bone interface or fixation. To assess the quality of the fixation: the prosthetic interface has a numerical score for components femur, tibia and patella. The scoring system for each of the three components is determined by measuring the width of the radiolucent lines for each of the zones in millimeters for each of the three components. The total widths are added for each zone for each of the three components. This total produces a numerical score for each component. Example for interpretation for a seven-zone tibial component: 4 or less and nonprogressive is not significant; 5-9 should be closely followed for progression; and 10 or greater signifies possible or impending failure regardless of symptoms.

  2. Assesment of health-related quality of life using the EQ-5D score [10 years]

    Euroqol-5 dimensions by the EuroQol Group (EQ-5D) consists of a descriptive system of health-related quality of life by a questionnaire and a thermometer scale. The Questionnaire comprises five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) with each 5 levels: no problems (level 1), slight problems (level 2), moderate problems, (level 3) severe problems (level 4) and extreme problems (level 5). The digits for the five dimensions can be combined into a 5-digit number and may be converted to a score (maximum is 1), defined by the health state classification. The Thermometer generates a self rating of current health-related quality of life and has end points of 100 (best imaginable health state) at the top, and 0 (worst imaginable health state) at the bottom. It should be used with the 5-digit health state classification to build a composite picture of the respondent's health status.

  3. Safety and performance of the device by recording all adverse events [10 years]

    assessment of all occured adverse events

  4. Calculation of survivorship using revision of prosthesis as the failure event [10 years]

    survivorship calculation by Kaplan-Meier technology

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Inclusion criteria should be in accordance with Indications for Use for Vanguard-ROCC® Knee

System specifically:
  • Painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more compartments are involved.

  • Correction of varus, valgus, or posttraumatic deformity.

  • Correction or revision of unsuccessful osteotomy, or arthrodesis.

Additional inclusion criteria include:
  • Male or female.

  • 18 years of age or older

  • Subjects willing to return for follow-up evaluations

Exclusion Criteria:

Exclusion criteria should be in accordance with Absolute and Relative Contraindications for Use for Vanguard-ROCC Knee system: Absolute contraindications include: infection, sepsis, osteomyelitis, and failure of a previous joint replacement.

Relative contraindications include:
  • Uncooperative patient or patient with neurologic disorders who are incapable of following directions,

  • Osteoporosis,

  • Metabolic disorders which may impair bone formation,

  • Osteomalacia,

  • Distant foci of infections which may spread to the implant site,

  • Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram,

  • Vascular insufficiency, muscular atrophy, neuromuscular disease,

  • Incomplete or deficient soft tissue surrounding the knee.

Contacts and Locations

Locations

Site City State Country Postal Code
1 ZNA Jan Palfijn Merksem Belgium
2 Sydvestjysk Hospital Grindsted Denmark
3 Hvidovre University Hospital Hvidovre Denmark
4 Clinique Pasteur Guilherand-Granges France
5 Clinique des Fontaines Melun France
6 Clinique d'Argonayy Pringy France
7 Clinique d'Argonay Pringy France
8 Clinique du Renaison Roanne France
9 South West London Elective Orthopaedic centre - EPSOM General Hospital Epsom United Kingdom

Sponsors and Collaborators

  • Zimmer Biomet

Investigators

  • Study Director: Paola Vivoda, Zimmer Biomet

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zimmer Biomet
ClinicalTrials.gov Identifier:
NCT03664791
Other Study ID Numbers:
  • BMETEU.CR.EU32
First Posted:
Sep 11, 2018
Last Update Posted:
May 10, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 10, 2022